Search
Gameto CEO Dina Radenkovic talks about running a women's health biotech, the development of Fertilo, work on menopause, and more
She describes how Fertilo is being developed to replace hormonal injections and shorten IVF and egg freezing times. Plus, how recent...
Sep 24, 2024
Cambridge UK's PhoreMost, a biotech that specializes in novel ligase discovery for protein degradation and molecular glues, topped up its series B to over $50M this month
CEO Neil Torbett describes the SITESEEKER target ID platform that is the company's foundation. More color on individual programs will be dis
Sep 24, 2024
Zurich based Araris Biotech is developing an ADC conjugation technology that allows for the use of multiple payload classes simultaneously
Acting CEO Dragan Grabulovski describes how they are able to achieve this, the benefits of having multiple payload classes at once, and...
Sep 24, 2024
The CEO of France's Orano Med gives an overview of the radiopharmaceutical approach and why he believes alpha emitters are the way to go
Julien Dodet describes Orano Med's 'lead 212' approach, and discusses pipeline programs, including partnerships with Molecular Partners...
Sep 23, 2024
The Co-Founder & CEO of Zurich based Molecular Partners describes their DARPin technology platform and how it is being put to use
Patrick Amstutz discusses the properties of DARPins that make them ideal building blocks of multispecifics and use cases such as immuno...
Sep 23, 2024
Zurich based CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue
Co-Founder & CEO Christian Leisner describes the M-gager platform and how it allows the company to have high specificity to targets, and...
Sep 23, 2024
Phoenixville, PA based PleoPharma is readying a phase 3 study of its therapy to treat cannabis withdrawal
Co-Founder & CEO Ginger Constantine describes how some people are affected by cannabis withdrawal and discusses the dual action medicine...
Sep 22, 2024
BaseCure Therapeutics is a Delaware area startup that is working on siRNAs for cardiometabolic diseases like hypertension and obesity
Acting CEO Jing Yang says the company's obesity approach will try to avoid the muscle wasting that comes with GLPs by focusing on the fat...
Sep 22, 2024
The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more
Gunilla Osswald talks about the global approvals Leqembi has received, she makes the case for a European approval, and talks about what...
Sep 21, 2024
Stockholm based Guard Therapeutics is trying to harness the natural properties of A1M (alpha-1-microglobulin) to protect the kidney
CEO Tobias Agervald explains how the lead program RMC-035 is being tested in conjunction with open heart surgery while smaller fragments...
Sep 21, 2024
Sweden's Anocca is a TCR-T company with a unique approach that is going after unique targets, its first CTA will be filed soon
Co-Founder and CEO Reagan Jarvis describes Anocca's TCR mapping, discovery, and engineering approach, as well as why they have chosen...
Sep 21, 2024
Plymouth Meeting based Geneos Therapeutics is developing DNA-based personalized therapeutic cancer vaccines
Founder and CEO Niranjan Sardesai describes why is believes a personalized approach is important and how Geneos is working on the...
Sep 20, 2024
Houston/Philadelphia based ImmunoGenesis is trying to turn cold tumors hot with a PD‑L1/PD‑L2 dual‑specific inhibitor
CEO Jim Barlow explains the unmet need and how the company is going after cancers such as triple-negative breast, colorectal, and ovarian...
Sep 20, 2024
Pittsburgh based Neuro-Innovators is developing three drugs to improve neuroplasticity to enhance the effectiveness of rehab post-stroke
Co-Founder and CEO Howison Schroeder describes this unmet need for chronic stroke patients and how Neuro-Innovators is working on a...
Sep 20, 2024
With expertise in delivering drugs to the liver, Medivir recently had data at ESMO for its lead liver cancer drug, fostrox
CEO Jens Lindberg describes the recent ESMO data and the next steps for this program. And he covers two others that are available for...
Sep 19, 2024
Vicore Pharma's CEO describes the rationale for using angiotensin II type 2 receptor agonists in IPF
Ahmed Mousa describes what excited him to join the company from the U.S. one year ago, the unmet need that still exists in this large...
Sep 19, 2024
Basilea, a profitable anti-infectives company, today landed a contract with BARDA worth up to $268M to develop antifungals and antibiotics
CEO David Veitch describes the news and expands on the success of Basilea's business model.
Sep 19, 2024
BioInvent's CEO highlights TNFR2 data recently presented at ESMO, and more in the company's pipeline
Martin Welschof describes this target that BioInvent is at the forefront of, including single agent data they have seen, and covers other...
Sep 19, 2024
The co-founder of Stockholm's Stratipath talks digital pathology and what it was like to spin out of the prestigious Karolinska Institute
Johan Hartman introduces us to the Karolinska Institute, where his company has benefitted from its Innovations arm, and describes how...
Sep 18, 2024
Oxford BioTherapeutics' OGAP platform, a cancer specific membrane protein library, has enabled the company to find cancer targets for its own pipeline and partners alike
CEO Christian Rohlff describes the expertise the company has build and describes pipeline assets, including partnerships with Boehringer,...
Sep 18, 2024
.png){kind=logo}
